GlassScriptPhysician profile
Tony Kastoon
NPI 1184636235
$39,552.40
in general payments reported to CMS, 2019-2025
56 companies · $12K in 2025
The $12K reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,312 · 2020: $4,437 · 2021: $2,723 · 2022: $3,778 · 2023: $5,212 · 2024: $4,584 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $4,500 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $900 · Travel and Lodging: $264 · Education: $127 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,452.99 |
| Consulting Fee | $4,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $900.00 |
| Travel and Lodging | $263.66 |
| Education | $127.10 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $7,992.90 | 2019-2025 | Uplizna, Tepezza, Evenity |
| Merck Sharp & Dohme LLC | $7,330.33 | 2019-2021 | |
| Novo Nordisk INC | $3,365.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $2,605.46 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $2,424.36 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $1,943.45 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Mannkind Corporation | $1,770.88 | 2019-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,543.73 | 2020-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $1,266.07 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $838.46 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $796.65 | 2021-2025 | |
| Insulet Corporation | $610.09 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $585.91 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Ascendis Pharma Endocrinology INC | $433.53 | 2024-2025 | Yorvipath |
| Medtronic, INC. | $433.04 | 2021-2025 | Minimed 780g |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $407.34 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $397.40 | 2020-2025 | |
| Madrigal Pharmaceuticals | $353.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Corcept Therapeutics | $346.33 | 2019-2025 | Korlym |
| Recordati_rare_diseases_inc. | $337.41 | 2020-2025 | Isturisa, Signifor Lar |
| Antares Pharma, INC. | $302.82 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Radius Health, INC. | $274.16 | 2019-2025 | Tymlos |
| Horizon Therapeutics Plc | $240.25 | 2019-2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $234.71 | 2022-2025 | |
| Esperion Therapeutics, INC. | $233.74 | 2021-2025 | Nexletol |
| Acella Pharmaceuticals, LLC | $208.99 | 2023-2025 | NP Thyroid 60 |
| Embecta Corp. | $201.31 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Beta Bionics, INC. | $196.32 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Vistapharm, INC. | $178.25 | 2021 | |
| Janssen Pharmaceuticals, INC | $173.12 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $148.99 | 2023-2024 | Inpefa |
| Becton, Dickinson and Company | $130.59 | 2022 | |
| Ionis Pharmaceuticals, INC. | $112.82 | 2025 | Tryngolza |
| Kyowa Kirin, INC. | $111.15 | 2023-2025 | |
| Cequr Corporation | $110.30 | 2023-2025 | Cequr Simplicity |
| Medtronic Minimed, INC. | $97.99 | 2019-2020 | |
| Ascensia Diabetes Care US INC. | $95.92 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $63.93 | 2021-2024 | Strensiq |
| Regeneron Healthcare Solutions, INC. | $62.80 | 2019-2022 | |
| Sequel Med Tech, LLC | $62.39 | 2025 | Twiist |
| Amarin Pharma, INC. | $61.90 | 2021-2022 | |
| Amryt Pharma Holdings LTD | $56.88 | 2022-2023 | Mycapssa |
| Halozyme INC | $50.57 | 2023 | |
| Neurocrine Biosciences, INC. | $48.35 | 2025 | |
| Pfizer INC. | $46.59 | 2019-2024 | |
| Currax Pharmaceuticals LLC | $42.18 | 2023-2025 | Nexletol, Contrave |
| Averitas Pharma INC. | $40.14 | 2025 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $38.62 | 2020 | |
| Ibsa Pharma INC. | $34.11 | 2020-2021 | |
| Tolmar, INC. | $31.61 | 2024 | |
| Lifescan, INC. | $17.67 | 2020 | |
| Acerus Pharmaceuticals Corporation | $17.64 | 2022 | |
| Nevro Corp. | $14.57 | 2023 | Senza |
| Echosens North America, INC. | $14.26 | 2023 | Fibroscan |
| Amphastar Pharmaceuticals, INC. | $13.08 | 2024 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Kastoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.